Oppenheimer Begins Coverage on ProQR Therapeutics (NASDAQ:PRQR)

Analysts at Oppenheimer assumed coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research note issued on Friday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $15.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price objective suggests a potential upside of 485.94% from the company’s previous close.

PRQR has been the topic of a number of other research reports. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. JMP Securities reissued a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR traded down $0.06 during mid-day trading on Friday, reaching $2.56. 41,218 shares of the company’s stock were exchanged, compared to its average volume of 213,678. The firm has a market capitalization of $209.10 million, a PE ratio of -8.00 and a beta of 0.30. ProQR Therapeutics has a one year low of $1.61 and a one year high of $4.62. The business’s fifty day simple moving average is $3.26 and its two-hundred day simple moving average is $2.50.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRQR. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after buying an additional 51,663 shares in the last quarter. OneDigital Investment Advisors LLC grew its position in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).